ReviewAsian journal of pharmaceutical sciences2025
Extracellular vesicles in cancer immunotherapy: Therapeutic, challenges and clinical progress.
Review in Asian journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Extracellular vesicles for next-gen therapeutics and drug delivery.Molecular biomedicine · 2026Review
- Proteomic Stability and Ex Vivo Compatibility of a Processed Phospholipoproteic Secretome-Derived Formulation.Pharmaceutics · 2026Article
- Exosomal P4HA3: a promising biomarker for diagnosis and prognosis in gastric cancer.Translational cancer research · 2026Article
- Editorial: Immune-genetic dynamics in disease progression and therapeutic strategies.Frontiers in immunology · 2026Article
- Glioma-derived extracellular vesicles as drivers of immunotherapeutic resistance: mechanisms of immune reprogramming and metabolic intervention.Frontiers in immunology · 2026Review
- Therapeutic potential and mechanistic insights into adipose-derived stem cells and mesenchymal stem cell-derived exosomes in patients with Crohn's disease-associated fistulas: challenges and future perspectives.Stem cell research & therapy · 2025Review
- Extracellular matrix dysregulation in aging, calcification, and cancer diseases: insights into cellular senescence, inflammation, and novel therapeutic strategies.International journal of biological sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a major global concern due to its high mortality rate. Tumor immunotherapy has revolutionized cancer treatment. However, low response rates and immune-related complications remain challenges. Extracellular vesicles (EVs), including exosomes, have emerged as promising therapeutic tools for various pathological conditions, especially cancer. Evidence indicates that changes in the quantity and composition of EVs can influence the immunosuppressive tumor microenvironment, potentially affecting the effectiveness of immunotherapy. Exploiting EVs for immune sensitization has generated significant clinical interest. This review provides an in-depth understanding of the origin of EVs, their therapeutic applications (such as drug delivery nanoplatforms and cancer immunotherapies, including vaccines), diagnostic potential as tumor biomarkers, ongoing EV-based clinical trials, and the challenges encountered in EV-based cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.